Gongxin-KY Accelerates Global Expansion for Lung Cancer Drug; Expects Growth in China
NQ Score
49/100
N1 Content Completeness
9
AI Summary (NQ-processed)
Gongxin-KY expects growth in the second half of the year following sales strategy optimization for its lung cancer drug PTS302 in China, while accelerating international licensing.
AI Analysis
Frequently Asked Questions
- Q: What is the new drug?
- A: PTS302 for lung cancer.